FDA Workshop Highlights First Engineered B-Cell Therapy for Pediatric Patient
The U.S. Food and Drug Administration (FDA) is hosting a workshop titled 'Advancing Pediatric Cell and Gene Therapy Clinical Trials,' where Immusoft, a biotechnology company, will present a clinical case review of the world's first engineered B-cell therapy administered to a pediatric patient. This therapy, known as ISP-001, is designed to treat Mucopolysaccharidosis type I, a rare genetic disorder. The therapy uses the patient's own B cells to produce therapeutic levels of the enzyme α-L-iduronidase, which is deficient in patients with this condition. The FDA has granted ISP-001 Orphan Drug, Rare Pediatric Disease, and Fast Track designations. The workshop is co-hosted by the Alliance for Regenerative Medicine and will feature insights from Immusoft's ongoing Phase I trial. 
